Is the Immuneering (IMRX) investment thesis intact?

Yes. Readouts currently rates the Immuneering Thesis Intact. MAPKeeper enrollment advances; expanded trial leaves less financial cushion.

What is the next catalyst for Immuneering (IMRX)?

The next dated event is Phase 2 start for Atebimetinib, expected 4Q 2026, as stated by the company.

How long will Immuneering's cash last?

Immuneering has said its cash will fund operations into the fourth quarter of 2028 (guidance as of October 29, 2026). It reported $166 million in cash as of September 30, 2026.

IMRXImmuneering Corporation

Market reactionShares fell 10% on Nov 5.

IntactLast material event Aug 5, 2026 · Updated Oct 30, 2026

MAPKeeper enrollment advances; expanded trial leaves less financial cushion

Immuneering is a late-stage clinical company developing atebimetinib, a once-daily oral MEK inhibitor, for first-line metastatic pancreatic cancer; it is not approved.

Immuneering's case rests on atebimetinib plus mGnP in first-line pancreatic cancer. Single-arm Phase 2a median survival was 17.3 months; randomized confirmation remains central. MAPKeeper 301 enrollment is ahead of schedule, expanding to approximately 570 patients; topline guidance remains mid-2028. Updated Phase 2 follow-up is expected in 1H 2027. The lung cancer combination offers expansion potential, with first dosing planned in 4Q 2026. Management expects cash to fund operations into the fourth quarter of 2028, leaving less financial cushion.

Thesis checklist

0 risks need attention

Select a row for evidence

What must be trueStateNext proof

MAPKeeper 301 confirms a survival benefitAwaiting evidenceFurther enrollment progress and any formal revision to mid-2028 topline guidance.Next: Further enrollment progress and any formal revision to mid-2028 topline guidance.

Why it is in this state

The evidence, what would weaken it and the source filing

Phase 2a survival holds upSupportedUpdated survival and tolerability from the same mGnP cohort in 1H 2027.Next: Updated survival and tolerability from the same mGnP cohort in 1H 2027.

Why it is in this state

The evidence, what would weaken it and the source filing

Lung cancer combination trial startsAwaiting evidenceConfirmation of first-patient dosing in the Phase 2 lung cancer combination trial.Next: Confirmation of first-patient dosing in the Phase 2 lung cancer combination trial.

Why it is in this state

The evidence, what would weaken it and the source filing

Cash lasts past the Phase 3 readoutSupportedNext cash update and whether spending preserves funding beyond the pivotal readout.Next: Next cash update and whether spending preserves funding beyond the pivotal readout.

Why it is in this state

The evidence, what would weaken it and the source filing

Next decision point

Does longer Phase 2a follow-up sustain the survival case?

Tests: Phase 2a survival holds up

1H 2027

Do updated survival and tolerability in the same atebimetinib plus mGnP cohort sustain the rationale for pivotal development?

Strong, inconclusive and weak outcomes

What to look for in the result and how each would move the checklist

Questions to investigate

History

Price and material events

Select an event marker to read the update below. Marker colors show Thesis status.

IntactCurrentClinical

+1.6%Aug 5, 2026

MAPKeeper enrollment advances; expanded trial leaves less financial cushion

IntactClinical

-22.1%Jun 1, 2026

Atebimetinib's Phase 3 MAPKeeper 301 trial tests whether striking Phase 2a OS data in first-line PDAC translates to a registrational win in mid-2028

IntactClinical

-43.2%Jan 7, 2026

Phase 2a atebimetinib + mGnP 12-month OS data in pancreatic cancer

IntactClinical

+52.2%Jun 17, 2025

Atebimetinib + mGnP Phase 2a interim data in first-line pancreatic cancer

About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.

Pipeline

Pancreatic cancer· first-line

atebimetinib · 1 upcoming · 5 completed

Phase 3 Data: ToplineMAPKeeper 301Pivotal

Mid 2028

Non-small cell lung cancer· advanced

atebimetinib · 2 upcoming

Phase 2 Study Initiation

4Q 2026

Phase 2 Data: Interim

Late 2027

Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.

Quick answers

Is the Immuneering (IMRX) investment thesis intact?: Yes. Readouts currently rates the Immuneering Thesis Intact. MAPKeeper enrollment advances; expanded trial leaves less financial cushion.
What is the next catalyst for Immuneering (IMRX)?: The next dated event is Phase 2 start for Atebimetinib, expected 4Q 2026, as stated by the company.
How long will Immuneering's cash last?: Immuneering has said its cash will fund operations into the fourth quarter of 2028 (guidance as of October 29, 2026). It reported $166 million in cash as of September 30, 2026.

Other companies we cover in these diseases

Pancreatic cancer: Verastem (VSTM)Elicio Therapeutics (ELTX)
Non-small cell lung cancer: Calidi Biotherapeutics (CLDI)Black Diamond Therapeutics (BDTX)

Disease areas: Lung cancer, Gastrointestinal cancers, Other cancers
Catalyst calendar · Upcoming FDA decisions · Thesis changes

Competitive landscape

9 peers tracked

Financial snapshot

Dates and calculation details

Cash: Market-data provider estimate; measurement period unavailable.

Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.

Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.

Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.

Runway: No underlying guidance available.